Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus concurrent chemoradiation and adjuvant temozolomide for newly diagnosed diffuse midline glioma
ChiCTR2300071855Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anlotinib in diffuse midline glioma (DMG) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Overall survival. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on ChiCTR2300071855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071855.